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The incidence of weak D has been reported to be between 0.23
and 0.5 percent in Europe and 3.0 percent in the United States. All
studies were performed before the introduction of monoclonal
anti-D reagents. Using current commercial reagents, this study
evaluated D+ samples for the presence of weak D. D+ donors,
typed by the Olympus PK 7200, using diluted monoclonal blend
anti-D and diluted polyclonal anti-D, were selected by sampling
batches of 100 to 200 samples from the previous day’s collection.
Anti-D reagents used on the Olympus PK 7200 are required to
detect RBCs with the weak D phenotype which do not agglutinate
at immediate spin (IS) when tested with polyclonal anti-D by
manual tube methods. More than 95 percent of donors tested were
Caucasian. Using tube tests with two different monoclonal blend
anti-D reagents and one polyclonal anti-D typing reagent, the
presence or absence of the D antigen was evaluated after the IS
reading. Donors found negative or weakly positive (< 2+) at IS
were further typed for weak D by the IAT. The weak D samples
were RHD genotyped by allele-specific PCR. Of 1005 donors
tested, 4 (0.4%) were classified as weak D by one or more anti-D
reagents. Polyclonal anti-D reagent demonstrated weaker reactions
when compared with the monoclonal blends. All weak D samples
were found positive for exon 4, intron 4, and exon 10, a finding
consistent with most D+ samples. The incidence of weak D found
in this study is not significantly different from that found in earlier
studies using polyclonal anti-D reagents. Immunohematology
2005;21:152–4.
Key Words: incidence of weak D, anti-D typing
reagents
The D antigen is carried on an integral protein
inserted into the RBC membrane. It is proposed that
point mutations that cause amino acid changes in the
intracellular or transmembrane portions of the protein
result in less protein being inserted into the
membrane. This leads to a quantitative difference in
reactivity with anti-D reagents when testing D+ and
weak D RBCs. Depending on the anti-D reagent, RBCs
with a weak D phenotype may not react or may react
weakly (< 2+) in direct agglutination tests, but are
reactive by the IAT.
Point mutations in extracellular loop regions or
genetic mutations, such as recombination or frameshift
mutations leading to absence of portions of the Rh
protein, can result in partial D antigens. Some anti-D
reagents can react with partial D RBCs by direct
agglutination while others require IATs.
The incidence of serologically defined weak D has
been reported to be between 0.23 and 0.5 percent in
Europe and 3.0 percent in the United States. In 1974,
Garretta reported an incidence of 0.56 percent with
203,240 samples typed with a Groupamatic using
polyclonal anti-D.1 In 1989, Contreras reported 49 out
of 16,484 donors (0.3%) typed as weak D by the
Kontron Groupamatic G2000.2 Of these 49 donors, 27
were initially typed as weak D by the Kontron. In
addition, 14 of 87 Groupamatic-typed D–, C+, E–
donors and 8 of 90 D–, C–, E+ Groupamatic-typed
donors were confirmed weak D. All 49 donors were
confirmed weak D by a manual IAT.
An incidence of 0.23 percent (32 of 13,500) weak
D donors was found in the Netherlands when testing
with various anti-D reagents, including four polyclonal
anti-D with enhancers, four monoclonal anti-D available
in the Netherlands, two modified IgG anti-D, and
bromelin anti-D.3 In this study, weak D was identified
as samples typing D– with at least two of these anti-D
reagents.
In the United States, Stroup Walters reported an
incidence of 3.0 percent in typing 23,000 donors in
1988 with at least two reagents.4 This study was
performed prior to the  introduction of monoclonal
anti-D reagents in the United States.
Materials and Methods
Sample selection
D+ blood donors, typed by the Olympus PK 7200
(Olympus America, Inc., Melville, NY) using diluted
monoclonal blend anti-D and diluted polyclonal anti-D,
were selected by sampling batches of 100 to 200
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samples from the previous day’s collection. A total of
1005 D+ donor samples were tested. All samples were
collected in EDTA-containing tubes (Becton Dickinson
and Co., Franklin Lakes, NJ). More than 95 percent of
samples were from Caucasian donors.
Anti-D reagents used on the PK 7200 included anti-
D monoclonal blend Gamma-clone (ImmucorGamma,
Houston,TX) diluted 1 to12 with physiologic saline and
polyclonal anti-D (ImmucorGamma) diluted 1 to 8 with
6% dextran (Mol.wt. 68800). The optimal working
dilution was determined for each lot of anti-D and Rh
control reagent. Following the Olympus PK 7200
Operator’s Manual, a series of dilutions were made for
each reagent and tested with 16 D+, 50 D–, and 8 weak
D RBC samples. All donor RBCs were treated with 0.8%
bromelin. All batches typed on the PK 7200 included
D–, D+, and weak D controls.
Testing for D antigen
D antigen testing by conventional tube method was
performed using the following anti-D reagents:
polyclonal anti-D (ImmucorGamma, Houston,TX), anti-
D monoclonal blend, Gamma-clone (ImmucorGamma,
Houston, TX), and anti-D monoclonal blend, Series 4
(ImmucorGamma, Norcross, GA). RBCs found to be D–
or weakly D+ (< 2+) were further tested for weak D by
the IAT. A positive result in the IAT defined weak D in
this study.
RHD genotyping
All weak D samples were RHD genotyped by allele-
specific PCR. DNA was prepared from blood samples
using one of the following methods: QIAamp Blood Kit
(Qiagen, Venlo, the Netherlands), PUREGENE (Gentra
Systems, Minneapolis, MN), or MagNA Pure LC DNA
Isolation Kit I (Roche, Indianapolis, IN). RHD
genotyping was performed in two multiplex PCR
reactions. The first reaction detected intron 4 and exon
10.5,6 The second reaction detected exon 4, including
the position of the 37-bp insert found in the RHD
pseudogene.7 PCR products were analyzed by agarose
gel electrophoresis in the presence of ethidium
bromide followed by documentation by UV
illumination.
Results
Four donors (0.4%) were classified as weak D by
one or more anti-D reagents (Table 1). Polyclonal anti-
D reagent demonstrated weaker reactions when
compared with the monoclonal blends. Gamma-clone
monoclonal blend anti-D showed the strongest
reactions on direct agglutination.
All weak D RBC samples were found positive for
exon 4, intron 4, and exon 10, a finding consistent with
most D+ RBC samples.
Discussion
When testing 1005 D+ donors, as defined by
testing with the Olympus PK 7200, we found the
incidence of weak D to be 0.4 percent. This is not
significantly different from the results of earlier studies
using polyclonal reagents,where the incidence of weak
D was reported to be between 0.23 and 3.0 percent.
Monoclonal reagents showed similar results to those
seen with polyclonal reagents when using less than 2+
agglutination as the defining limit to determine the
presence or absence of D antigen by direct
agglutination.
It is possible that the incidence of weak D is higher
than that found in our study because only donors who
typed D+ on the Olympus PK 7200 were studied.
Donors with very weakly expressed D antigens not
detected by the Olympus methodology may have been
missed. Gassner and colleagues performed molecular
analysis on 1700 serologically typed D–, C+ or E+ RBC
samples from Central European blood donors. Eighty-
nine had various forms of RHD alleles when screened
for RHD-specific DNA sequences.8 Five of these
donors would have presumably been detected by
serologic weak D testing. Wagner et al.9 investigated
1068 donors who serologically typed D–. Of these
donors, 48 carried the RHD gene and all were C or E
antigen positive. In addition, 7374 RBC samples
determined to be D–, C–, E–, c+, e+ were tested and 2
RHD positive donors were found. Five donors in all
were subsequently typed as weak D.9 The frequency of
weak D in individuals typing as D– is low, on the basis
of these two studies.
Table 1. Results of donor weak D RBCs with anti-D reagents
Monoclonal Monoclonal 
Polyclonal blend blend Immucor
Anti-D Gamma-clone (Series 4)
Sample IS IAT IS IAT IS IAT
1 +/–* 2+ w+† 2+ w+ 2+
2 0 2+ 1+ 3+ w+ 3+
3 0 w+ w+ 2+ 0 2+
4 +/– 3+ 1+ 3+ +/– 3+
*+/–  = weak granularity in the RBC suspension. A few macroscopic agglutinates in a
turbid red background.
†w+  = tiny agglutinates in a turbid red background (free RBCs)
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In our study all weak D samples were genotyped to
confirm the presence of the RHD gene and to look for
unusual PCR results, in an attempt to determine
whether the weak D status was due to quantitative or
qualitative differences. All four weak D samples tested
as having “normal” RHD genes. It is unlikely that these
weak D samples are any of the common partial D
types. DVI, the most common partial D among
Caucasians, reacts only in the IAT using a test tube
method, while R0
Har reacts with Gamma-clone anti-D
upon immediate spin (IS) and does not react with
Ortho BioClone anti-D reagent. Partial D categories,
including DII, DIII, DIV, and DVa, are detected by
monoclonal anti-D reagents upon IS.10 The donors in
our study all reacted weakly by direct agglutination
with both examples of monoclonal anti-D used but
reactivity was significantly enhanced in the IAT used to
detect weak D. In addition, our PCR method would
have detected the presence of DVI and R0
Har, as DVI
would be negative for exon 4 and intron 4 and R0
Har
would have tested as D–. As most weak D phenotypes
are due to point mutations11 that would not be
detected by our PCR assay, our results are consistent
with those samples having either a RHD allele
encoding a weak D phenotype, or having RHC in trans
to D, causing weakened D antigen expression.
While only serologically determined D+ donors
were tested in this study and the number tested was
relatively small, the incidence of 0.4 percent compares
to that previously found by serologic methods. Further
molecular studies on the U.S. donor population, like
those reported by Gassner and Wagner, may provide
further information on the incidence and significance
of weak D antigen.
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